High levels of TNFα in patients with COVID-19 refractory to tocilizumab.
作者信息
Danlos F X, Ackermann F, Rohmer J, Roumier M, Marabelle A, Michot J M
机构信息
INSERM U1015, Gustave Roussy Villejuif, France.
Hôpital Foch, Suresnes, France.
出版信息
Eur J Cancer. 2021 May;149:102-104. doi: 10.1016/j.ejca.2021.01.056. Epub 2021 Mar 20.
Abstract
摘要
相似文献
1
High levels of TNFα in patients with COVID-19 refractory to tocilizumab.对托珠单抗难治的COVID-19患者中肿瘤坏死因子α水平较高。
Eur J Cancer. 2021 May;149:102-104. doi: 10.1016/j.ejca.2021.01.056. Epub 2021 Mar 20.
2
Treatment of COVID-19-induced refractory status epilepticus by tocilizumab.托珠单抗治疗新型冠状病毒肺炎所致难治性癫痫持续状态
Eur J Neurol. 2022 Sep;29(9):2861-2863. doi: 10.1111/ene.15440. Epub 2022 Jun 22.
3
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
4
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
5
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.托珠单抗用于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者：皮下注射与静脉输注对比
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
6
The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.托珠单抗、阿那白滞素和泼尼松龙对 COVID-19 患者抗 SARS-CoV-2 抗体反应的影响：一项前瞻性队列研究，采用多变量分析影响抗体反应的因素。
Int J Infect Dis. 2021 Apr;105:756-762. doi: 10.1016/j.ijid.2021.03.031. Epub 2021 Mar 15.
7
Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.测试托珠单抗对新冠肺炎肺炎患者的疗效。
J Comp Eff Res. 2021 Jun;10(8):625-627. doi: 10.2217/cer-2021-0050. Epub 2021 Apr 23.
8
Timing of Tocilizumab Use and COVID-19.托珠单抗的使用时机与新型冠状病毒肺炎
Respir Care. 2022 Mar;67(3):381-382. doi: 10.4187/respcare.09678.
9
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?托珠单抗降低重症 COVID-19 患者死亡率：我们应如何对其进行分级？
Br J Clin Pharmacol. 2022 Jul;88(7):3539-3541. doi: 10.1111/bcp.15283. Epub 2022 Mar 2.
10
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
引用本文的文献
1
Quantitative proteomics analysis of COVID-19 patients: Fetuin-A and tetranectin as potential modulators of innate immune responses.新冠肺炎患者的定量蛋白质组学分析：胎球蛋白-A和纤连蛋白作为先天免疫反应的潜在调节因子
Heliyon. 2023 Apr;9(4):e15224. doi: 10.1016/j.heliyon.2023.e15224. Epub 2023 Apr 9.
2
The Probable Protective Effect of Photobiomodulation on the Inflammation of the Airway and Lung in COVID-19 Treatment: A Preclinical and Clinical Meta-Analysis.光生物调节对 COVID-19 治疗中气道和肺部炎症的可能保护作用：一项临床前和临床的荟萃分析。
Adv Exp Med Biol. 2022;1376:29-44. doi: 10.1007/5584_2021_665.
3
Myeloid dysregulation and therapeutic intervention in COVID-19.COVID-19 中的髓系失调和治疗干预。
Semin Immunol. 2021 Jun;55:101524. doi: 10.1016/j.smim.2021.101524. Epub 2021 Nov 9.
本文引用的文献
1
An inflammatory cytokine signature predicts COVID-19 severity and survival.炎症细胞因子特征可预测 COVID-19 严重程度和存活情况。
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.
2
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.托珠单抗治疗重症新型冠状病毒肺炎患者：一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
3
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.新型冠状病毒肺炎肺血管内凝血病变的免疫机制
Lancet Rheumatol. 2020 Jul;2(7):e437-e445. doi: 10.1016/S2665-9913(20)30121-1. Epub 2020 May 7.
4
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.血清钙卫蛋白和异常髓系细胞亚群可区分 COVID-19 重症与轻症。
Cell. 2020 Sep 17;182(6):1401-1418.e18. doi: 10.1016/j.cell.2020.08.002. Epub 2020 Aug 5.
5
A minimal common outcome measure set for COVID-19 clinical research.用于 COVID-19 临床研究的最小通用结局指标集。
Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12.
6
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.一项关于托珠单抗在重症 COVID-19 患者中的超适应证使用的前瞻性开放、单臂多中心研究。
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532. Epub 2020 May 1.
7
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
8
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.迫切需要开展针对新型冠状病毒肺炎的抗肿瘤坏死因子疗法试验。
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件